Question 1

What are the potential risks and side effects of RP-A601?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) clinical trial (NCT05885412). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current management plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) clinical trial (NCT05885412). Contact the study team or your healthcare provider for specific answers.

Question 3

What monitoring will be done during and after treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) clinical trial (NCT05885412). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) clinical trial (NCT05885412). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) clinical trial (NCT05885412). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any other treatment options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM) clinical trial (NCT05885412). Contact the study team or your healthcare provider for specific answers.

What this study is about